Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry, announced today the addition of a Harro Höfliger Modu-C CS Containment at its New Jersey facility. The new equipment is the first capsule filling solution in North America to provide enhanced protection of employees and the environment from highly potent pharmaceutical products.
Many active pharmaceutical ingredients, including spray dried powders and inhalation products, are highly potent and require manufacturers to provide a permanent physical barrier to protect operators from the material. The Modu-C CS Containment, with a completely enclosed precision filling system, protects employees from exposure and offers in-containment, inline capsule polishing, 100% gross weight control, and a wet-in-place feature to minimize exposure risk during cleaning.
“Engineering controls offer a more advanced employee protection solution in the pharmaceutical manufacturing environment,” said Justin Lacombe, Ph.D., chief scientific officer of Experic. “Combined with the advanced Harro Höfliger filling technology, Experic has a complete solution for manufacturing highly potent drug products, complementing our specialized pharmaceutical spray drying and DPI development and manufacturing services.”
Experic, a contract development and manufacturing organization (CDMO) and pharmaceutical supply services company, supports every phase of a product’s life cycle from conception to clinical and commercial scale, across a range of dosing and packaging formats, including tablets, pellets, capsules, and low dose dry powder inhalation. From our state-of-the-art, Class A cGMP facility, we manage global delivery of the highest quality products, even for expedited projects, while providing unparalleled knowledge, expertise, and customer service. Learn more about our manufacturing and supply services at expericservices.com.
First solution in North America added at @ExpericServices New Jersey location to enhance protection for manufacturing high-potency pharmaceuticals.